Skip to search formSkip to main contentSkip to account menu

roscovitine

Known as: (2R)-2-((6-benzylamino-9-(propan-2-yl)-9h-purin-2-yl)amino)butan-1-ol, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
We sought to determine whether seliciclib (CYC202, R‐roscovitine) could increase the antitumor effects of doxorubicin, with no… 
Highly Cited
2005
Highly Cited
2005
We reported recently that roscovitine arrested human MCF-7 cancer cells at G2-M phase of the cell cycle and concomitantly induced… 
Highly Cited
2005
Highly Cited
2005
R-roscovitine (seliciclib, CYC202) is a cyclin-dependent kinase inhibitor currently in phase II clinical trials in patients with… 
Highly Cited
2004
Highly Cited
2004
The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is limited in many glioma cell lines… 
Highly Cited
2003
Highly Cited
2003
Frequent deregulation of cyclin-dependent kinase (CDK) activation associated with loss of cell cycle control was found in most of… 
Highly Cited
2001
Highly Cited
2001
Butyrolactone I (BL‐I) and Roscovitine (ROS), two specific and potent inhibitors of M‐phase promoting factor (MPF) kinase…